miRecule, Inc. has entered a strategic research collaboration with Rio Biofarma Brasil Ltda., part of Brazilian pharmaceutical group EMS S.A., to develop peptide-mediated delivery technologies for RNA therapeutics targeting tissues outside the liver. The agreement covers the development of peptide-RNA conjugates for as many as three targets, includes joint ownership of the resulting technology and is supported by an undisclosed equity investment in miRecule.
The collaboration addresses a problem that has shaped the RNA therapeutics industry for years. Designing an oligonucleotide that can silence or modify a disease-associated genetic signal is only one part of drug development. The molecule must also survive in circulation, reach the intended tissue, enter the relevant cells, escape intracellular compartments and produce a sufficiently durable pharmacological effect without generating unacceptable toxicity.
miRecule and Rio Biofarma are therefore not announcing a clinical candidate, regulatory submission or human trial. They are building an enabling technology that could eventually produce such candidates. No disease indications, individual targets, development timelines, nonclinical results or planned first-in-human dates were disclosed in the July 30 announcement.
That distinction is important. The partnership could broaden miRecule’s scientific and commercial reach if the peptide delivery system works across multiple tissues, but its present value lies in platform development, manufacturing preparation and risk-sharing rather than established therapeutic performance.
What does the miRecule and Rio Biofarma agreement commit each company to deliver?
Under the collaboration, miRecule will use its NAVIgGator platform to develop oligonucleotide payloads for up to three targets. Rio Biofarma will contribute peptide discovery, development and manufacturing capabilities, with the partners seeking to combine the oligonucleotides and peptides into conjugated molecules capable of reaching new tissue targets.
Rio Biofarma is also expected to manufacture products emerging from the programme at its facility in Brazil. The companies have retained opportunities to co-develop resulting products for international markets, although the announcement did not identify territories, development-cost allocations, commercial responsibilities, governance provisions or ownership rights for individual drug candidates.
The agreement gives both parties co-ownership of the developed delivery technology. That structure can align incentives during the research stage because neither company is acting solely as a fee-for-service provider. However, co-ownership can become more complicated when a programme advances into licensing, clinical development or regional commercialisation.
Future agreements may need to establish who controls target selection, regulatory strategy, intellectual property prosecution, sublicensing decisions and investment priorities. These questions are not signs of weakness in the collaboration, but they will become increasingly important if early research produces a viable candidate.
The equity investment adds another layer to the relationship. Rio Biofarma is not merely supplying peptides or contract manufacturing services. It is taking a financial position in miRecule while supporting the collaboration and the biotechnology company’s broader neuromuscular pipeline. The investment amount and valuation were not disclosed.
Why is extrahepatic delivery still a decisive bottleneck for RNA medicines?
RNA therapeutics can be designed to interfere with disease-associated gene expression with a level of sequence specificity that conventional small molecules may not achieve. Their practical reach, however, depends heavily on delivery.
The liver has been comparatively accessible because it naturally captures many circulating particles and because delivery technologies such as N-acetylgalactosamine conjugation can exploit highly expressed hepatic receptors. Comparable receptor and delivery systems have not been established across most other tissues.
Scientific reviews continue to describe efficient extrahepatic oligonucleotide delivery as a major translational limitation. Barriers can include limited tissue penetration, inadequate cellular uptake, poor endosomal escape, rapid clearance and insufficient exposure in the cell type responsible for the disease.
Peptides are being investigated as one possible solution because their sequences can be engineered for receptor binding, tissue penetration, cellular internalisation or intracellular trafficking. A peptide can theoretically function as an address label, a cellular entry mechanism or both.
The presence of a peptide does not automatically create effective delivery. The conjugate must retain the RNA payload’s activity, avoid excessive uptake in non-target tissues and remain stable enough to reach its destination. It must then release or present the oligonucleotide in a form that can engage its intracellular target.
These challenges explain why the new collaboration should be judged through pharmacokinetic, biodistribution and pharmacodynamic evidence rather than the number of targets initially selected.
How could peptide-RNA conjugates extend miRecule’s platform beyond its muscle-focused programmes?
miRecule has concentrated its recent corporate positioning on RNA therapeutics for rare neuromuscular diseases. Its most advanced disclosed programme, MC-DX4, is designed to suppress DUX4 expression in facioscapulohumeral muscular dystrophy and has been licensed to Sanofi. The companies expanded that collaboration in March 2026, with Sanofi remaining responsible for downstream clinical development and global commercialisation.
miRecule has also identified MC-DNM2 as a programme targeting centronuclear myopathy. Its existing strategy uses conjugated delivery systems to move RNA payloads into muscle, where silencing a disease-driving gene could address an underlying molecular mechanism rather than only managing downstream symptoms.
The Rio Biofarma agreement potentially widens this model. The partners describe an ambition to reach new extrahepatic tissues across multiple disease areas, suggesting that the collaboration may not be restricted to skeletal muscle or the two neuromuscular diseases already highlighted by miRecule.
That creates a potential platform expansion opportunity. A validated peptide delivery system could allow miRecule to apply its oligonucleotide design capabilities to neurological, immunological, oncological or other genetically defined conditions. EMS has previously indicated that the collaboration could eventually support work in several of these fields, although no specific programme has been publicly selected.
The word “could” is doing necessary work here. A delivery construct that performs well in one tissue may not translate into another. Receptor expression, vascular access, cell turnover, intracellular trafficking and disease biology differ substantially between muscle, tumours, immune cells and the central nervous system.
Each target will consequently require its own evidence package. Platform reproducibility may accelerate discovery, but it cannot replace candidate-specific toxicology and pharmacology.
What does Rio Biofarma’s manufacturing infrastructure add to the development strategy?
Rio Biofarma Brasil was created as a manufacturing operation for complex sterile injectable products and to support the research, development and commercial production needs of Rio Biopharmaceuticals and other NC Group companies. The company describes capabilities spanning analytical method development, microbiological testing, quality assurance, regulatory planning and sterile manufacturing.
Its Hortolândia facility was inaugurated in 2024 with an initial focus on synthetic peptides and complex injectable products, including liraglutide and semaglutide. EMS has reported annual capacity of up to 20 million medicine units at the site and has connected the facility to more than R$1.2 billion of investment in complex technology platforms over a longer period.
Those figures demonstrate industrial commitment, but they should not be interpreted as immediate capacity for 20 million peptide-RNA conjugate doses. Existing output capacity is tied primarily to the facility’s established peptide and injectable operations.
A novel conjugated oligonucleotide may require different processes, equipment configurations, analytical controls and release specifications. Manufacturing teams will need to control peptide synthesis, oligonucleotide quality, conjugation efficiency, impurities, linker stability, molecular consistency, formulation and sterile handling where applicable.
Bioconjugated oligonucleotides can also present safety questions arising from each component of the molecule, including the peptide, linker and RNA payload. Nonclinical programmes must therefore assess the complete conjugate rather than assuming that individually familiar components will behave predictably when combined.
The collaboration’s manufacturing integration is still strategically meaningful. Delivery technologies are often developed by research companies that later face difficult technology-transfer exercises when a programme enters formal development. Bringing an industrial partner into the design stage may help the parties identify synthesis, purification and scale-up problems before a candidate becomes locked into an impractical process.
Why does the equity investment matter even though its value remains undisclosed?
For miRecule, the investment provides capital without the public disclosure and immediate market scrutiny associated with a listed-company financing. The funds are intended to support both the Rio Biofarma collaboration and the company’s neuromuscular pipeline, although no allocation, runway extension or milestone-based funding schedule was provided.
The investment also gives Rio Biofarma exposure to value created outside the three-target research programme. If miRecule’s Sanofi-partnered asset, independent pipeline or broader conjugate platform advances, the strategic investor may benefit through its equity position even when it does not hold direct product rights.
For EMS, the transaction supports a gradual move from established pharmaceutical manufacturing and complex generic products towards proprietary genetic medicines. The company has framed the miRecule relationship as a co-development model involving molecule design, oligonucleotide production and potential future clinical development rather than the acquisition of a finished technology.
That strategy carries greater scientific risk than conventional pharmaceutical manufacturing, but it also offers access to intellectual property, development know-how and international product economics that may not be available through manufacturing alone.
The missing financial details limit any assessment of whether the arrangement provides miRecule with substantial development funding or represents a smaller strategic commitment. The more revealing indicators will be target selection, candidate nomination, nonclinical progress and any follow-on investment.
What evidence must be generated before the collaboration becomes a clinical asset?
The first meaningful test will be whether the partners identify peptides that deliver measurable quantities of an active oligonucleotide to the intended tissue and cell population. Tissue exposure by itself will not be enough. The payload must engage its target and produce the intended molecular effect at an exposure compatible with repeated or clinically practical dosing.
The partners will also need to examine distribution outside the target tissue. A delivery system that increases uptake everywhere may raise toxicity without improving the therapeutic index. Effective targeting requires a useful separation between the desired tissue and organs where accumulation could create unwanted effects.
Durability will influence the commercial profile. A conjugate requiring frequent administration may be difficult to position in rare chronic diseases unless dosing is convenient and tolerability remains acceptable. Conversely, a durable effect could reduce treatment burden but may complicate dose adjustment if unexpected toxicity emerges.
Candidate selection will then lead into formal chemistry, manufacturing and controls work, dose-range finding, safety pharmacology and regulatory discussions. The technology will remain preclinical until the companies nominate a candidate and generate the evidence required to support human testing.
The July announcement provided no candidate nomination target, investigational application timeline or clinical-development schedule. The nearest measurable milestones are therefore likely to be the disclosure of the first disease targets, presentation of biodistribution and gene-silencing data, confirmation of manufacturing reproducibility and selection of a development candidate.
How does the agreement fit miRecule’s broader Sanofi-linked neuromuscular strategy?
miRecule’s relationship with Sanofi provides external validation of interest in its RNA-conjugate approach, but it does not validate the new peptide platform. MC-DX4 uses miRecule’s established antibody-RNA conjugate strategy and is linked to a specific muscle disease programme. The Rio Biofarma collaboration introduces a different delivery component and a broader tissue ambition.
The two relationships could nevertheless reinforce one another. Experience gained through the Sanofi programme may inform oligonucleotide design, conjugate characterisation and development planning, while the Rio Biofarma work could create delivery options for programmes outside the scope of the Sanofi licence.
Commercially, this reduces miRecule’s dependence on a single partnered candidate. A successful multi-target peptide platform could generate wholly or jointly owned assets, additional licensing opportunities and a more diversified pipeline.
It also raises execution demands. miRecule must continue supporting its neuromuscular programmes while running a broader delivery-technology collaboration and coordinating manufacturing activities across the United States and Brazil. For a development-stage biotechnology company, scientific opportunity can expand faster than operational capacity.
What are the key takeaways from the miRecule and Rio Biofarma collaboration?
The agreement gives miRecule a strategic investor, a peptide-development partner and a potential manufacturing pathway for up to three RNA therapeutic targets. Rio Biofarma and EMS gain access to proprietary RNA design capabilities and a route into jointly owned genetic-medicine technology.
The collaboration is notable because it links drug discovery with manufacturing earlier than many biotechnology partnerships. That could improve developability and reduce later technology-transfer risk.
It remains an early research programme. There are no disclosed candidates, indications, human data or regulatory timelines, and the amount of capital committed has not been revealed.
The partnership’s value will therefore depend on whether peptide conjugation produces selective, pharmacologically active and manufacturable delivery outside the liver. The next important announcement will not be another broad statement about the potential of RNA medicine. It will be evidence that one of the selected conjugates reaches the right cells, silences the intended target and can be produced consistently enough to justify formal development.
